Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 80 clinical trials
Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology (NiCE)

This study aims to develop and implement a pediatric palliative care (PPC) program. It is an open-label, randomized trial (2:1 randomization) in pediatric oncology department of Children's

recurrent disease
  • 04 Oct, 2022
  • 1 location
tRNS Combined to Cognitive Training in Children With Dyscalculia

transcranial random noise stimulation (tRNS) over dorsolateral prefrontal cortex (DLPFC) or posterior parietal cortex (PPC), cerebral areas usually disrupted in individuals with DD, in addition to a usual

  • 25 Feb, 2022
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

primary peritoneal carcinoma.

cancer of the ovary
primary peritoneal carcinoma
peritoneal carcinoma
  • 14 May, 2022
  • 1 location
A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care

standard of care in patients with newly diagnosed FIGO III-IV ovarian, fallopian tube, or primary peritoneal carcinoma.

  • 14 May, 2021
  • 1 location
Pre-habilitation in Lung Surgery Candidates

We hypothesize that high intensity respiratory muscle training will improve ventilatory efficiency (VE/VCO2 slope) and will be associated with decreased PPC, decreased mortality and better

assisted ventilation
lung surgery
  • 09 May, 2022
  • 1 location
Preformed Pediatric Crown Zirconia Versus Preformed Pediatric Metal Crown (PPC Z-M)

and fracture of the PPC, the wear of the antagonist tooth, the gingival state near PPC using the indices Le and Silness to record plaque index (PI), gingival index (GI) and depth of the pocket (DI

  • 14 Feb, 2022
  • 4 locations
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

This phase II trial investigates the effect of irinotecan liposome and bevacizumab in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that shows less response to platinum therapy (platinum resistant), has come back (recurrent), or does not respond to treatment (refractory). Irinotecan liposome may help block the formation …

  • 14 Apr, 2022
  • 1 location
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

This phase II trial studies the side effects of ONC201 and paclitaxel and how well they work in treating patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent), or that does not respond to treatment (refractory). ONC201 is the first in its class …

  • 30 May, 2022
  • 1 location
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This phase II trial studies how well durvalumab and tremelimumab work in treating participants with ovarian, primary peritoneal, or fallopian tube cancer that has come back or does not respond to treatment. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, …

tumor cells
neutrophil count
platelet count
  • 04 Oct, 2022
  • 1 location
A Phase I Open-Label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab in Patients With Platinum Resistant or Refractory Ovarian Cancer (PROTA)

This is an open-label, phase 1, dose-escalation, multicenter and multinational trial evaluating the safety of oncolytic adenovirus TILT-123 in combination with Pembrolizumab in patients with platinum resistant or refractory ovarian cancer.

  • 23 Oct, 2022
  • 2 locations